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ImmunohistochemistryEvaluation of cell cycle using antibodies against nuclear proteins involved in regulating DNA replication has
gained special interest in the effort to predict biologic behavior of benign and malignant tumors. The aim of
this study was to analyze the expression of minichromosome maintenance 2, Ki-67, and geminin in oral nevi
andmelanomas. Expression of these cell proliferation markers was evaluated by immunohistochemistry in 49
oral melanocytic lesions, including 38 intramucosal nevi and 11 primary oral melanomas. The labeling index
of each proliferationmarker was assessed considering the percentage of cells expressing nuclear positivity out
of the total number of cells, counting 1000 cells per slide. Minichromosome maintenance 2, Ki-67, and
geminin were rarely expressed in intramucosal nevi, in contrast to oral melanomas, which showed high levels
of these cell proliferation markers, particularly minichromosome maintenance 2, indicating it is a more
sensitive marker in primary oral melanomas than Ki-67 and geminin. These results indicate that these
markers may be involved in the pathogenesis of oral melanomas and could be eventually useful as an
additional diagnostic tool for differential diagnosis of oral benign and malignant melanocytic lesions.+55 19210 65218.
.B. de Andrade).
vier OA license. © 2013 Elsevier Inc. Open access under the Elsevier OA license. 1. Introduction
Oral melanoma is a rare lesion, comprising 0.2% to 0.8% of all
melanomas, and contrary to its cutaneous counterpart, little is known
about its etiologic factors and molecular mechanisms involved.
Evaluation of cell cycle proteins by immunohistochemistry has gained
special interest in the effort to predict biologic behavior and to
differentiate benign and malignant tumors [1]. The minichromosome
maintenance (Mcm) proteins are essential for the initiation and
elongation of DNA replication and comprise 6 proteins, Mcm-2 to
Mcm-7 [2]. They have a fundamental role in DNA replication
regulation, and their deregulated expression has been used as a
prognostic indicator and also has been considered a novel class of
cellular proliferation marker [3,4]. Ki-67 has largely been used as a
tool to estimate the proliferation potential and patient's prognosis [2].
Geminin is thought to be a regulator of the process that inhibits DNA
re-replication, by binding Cdt1 and preventing the recruitment of
Mcm complex during S, G2, and early M phases of the cell cycle [4].Recent studies have shown that Mcm proteins and geminin could
be sensitive proliferation markers and may serve as novel biomarkers
to detect premalignant and malignant lesions [3-5]. The expression of
Mcm proteins and geminin has not yet been studied in oral benign
and malignant melanocytic lesions. Therefore, the objective of this
study was to determine by immunohistochemistry the expression of
the cell proliferation markers Mcm-2, Ki-67, and geminin in oral
melanocytic nevi and melanoma.
2. Materials and methods
Formalin-ﬁxed, parafﬁn-embedded tissue blocks were obtained
from 49 oral melanocytic lesions, corresponding to 38 intramucosal
nevi and 11 primary oral melanomas. All lesions were revised using
hematoxylin and eosin preparations to conﬁrm the diagnosis.
Patients with intramucosal nevi included 30 females and 8 males,
aged 16 to 67 years, located in hard palate (n = 13), buccal mucosa
(n = 11), gingiva (n = 10), and not speciﬁed (n = 4), whereas the
primary oral melanomas corresponded to 8 women and 3 men, aged
23 to 86 years, located in hard palate (n = 6), hard palate and upper
gingiva (n = 3), and upper gingiva (n = 2). Diagnosis of melanoma
was conﬁrmed by clinical and histologic characteristics, excluding
the presence of melanoma at other anatomical sites and,
Table
Antibodies used for immunohistochemical evaluation of 38 intramucosal nevi and 13
primary oral melanomas
Antibody Clone Dilution Source
Mcm-2 CRCT2.1 1:40 Novocastra Laboratories, Newcastle upon Tyne,
United Kingdom
Ki-67 MIB-1 1:100 Dako Corporation, Carpinteria, CA
Geminin EM6 1:50 Novocastra Laboratories
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histologically classiﬁed according to Prasad et al [6], and all cases
corresponded to level III (very deep invasion).
For immunohistochemical staining, 3-μm-thick sections mounted
on silane-coated glass slides were used. Brieﬂy, the sections were
deparafﬁnized and rehydrated in graded ethanol solutions. After
antigen retrieval with EDTA/Tris buffer (pH 9.0) in a microwave oven
(1380 W; Panasonic, São Paulo, Brazil), endogenous peroxidase
activity was blocked with 20% H2O2 using 5 cycles of 5 minutes
each. Overnight incubation with the primary antibodies for Mcm-2,
Ki-67, and geminin (Table) diluted in bovine serum albumin was
followed by incubation with the secondary antibody conjugated with
polymer dextran marked with peroxidase (Dako EnVision Labeled
Polymer; Dako, Glostrup, Denmark). Reactions were developedwith a
solution containing 0.6 mg/mL 3,3′-diaminobenzidine tetrahy-
drochloride (DAB) (Sigma, St Louis, MO) and 0.01% H2O2 and
counterstained with Carazzi's hematoxylin. Positive and negativeFig. 1. Expression of Mcm-2 in oral melanocytic lesions. As it was DAB to develop the reactio
the cytoplasm of benign and malignant melanocytes, but this does not interfere with the ana
nuclear expression of Mcm-2 only in basal and suprabasal epithelial cells of the normal oral m
positivity in neoplastic cells (immunoperoxidase, A and C, original magniﬁcation ×200; B acontrols were included in all reactions. Only nuclear staining was
considered positive. As we used DAB as the developer, the reactions
could be confounded by melanin in the cytoplasm of benign and
malignant melanocytes, but this was not a problem for interpretation,
as we used only nuclear markers.
The labeling index (LI) of each proliferation marker was assessed
considering the percentage of cells expressing nuclear positivity out of
the total number of cells, counting 1000 cells per slide. The slides were
examined under a Leica DMR microscope, and images were captured
using a Leica digital camera (Leica Microsystems, Inc, Buffalo Grove,
IL). Immunoreactive cells were counted randomly with a minimum of
10 high-power ﬁelds (×400), with the help of an image computer
analyzer (ImageJ, Image Processing and Analysis in Java).3. Results
The epithelial cells of the normal oral mucosa showed a similar
pattern of immunostaining for Mcm-2, Ki-67, and geminin, with
positivity restricted to the nuclei of basal epithelial cells, togetherwith
some cells in the immediate suprabasal layers, serving as an internal
positive control. The most superﬁcial cells of the epithelium were
negative in all cases. Minichromosome maintenance 2, Ki-67, and
geminin were rarely expressed in intramucosal nevi, with LI less than
1% in all cases. The location of expression of these markers was
heterogeneous, not involving preferential areas of nevus cells nests
(Figs. 1, 2, and 3).ns, the brown color of the positive reaction, at ﬁrst, can be confounded with melanin in
lyses of the results, as it was only nuclear markers. A and B, Intramucosal nevi showing
ucosa, serving as internal control. C-D, Invasive oral melanoma showing diffuse Mcm-2
nd D, original magniﬁcation ×400).
Fig. 2. Expression of Ki-67 in oral melanocytic lesions: intramucosal nevi showing nuclear Ki-67 expression in epithelial cells of the normal oral mucosa, serving as an internal
positive control, whereas the nevi are negative (A and B), and invasive oral melanoma expressing nuclear positivity for Ki-67 in the tumor cells (C and D) (immunoperoxidase, A and
C, original magniﬁcation ×200; B and D, original magniﬁcation ×400).
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were 42.5% (range, 15.5%-65%), 31.7% (range, 10.3%-52.7%), and 10.5%
(range, 6.8%-17.3%), respectively. Although the expression of Mcm-2
was higher than Ki-67 and geminin, the pattern was similar for the 3
markers, with nuclear immunoreactivity diffusely spread in the tumor
cells (Figs. 1, 2, and 3).4. Discussion
Melanoma is known to exhibit aberrant expression of proliferation
markers, and these abnormalities are considered important steps in
the genesis and progression of melanoma [4]. In this study, we
evaluated the immunohistochemical expression of the proliferation
markers Mcm-2, Ki-67, and geminin in 38 intramucosal nevi and 13
primary oral melanomas. There are few studies about expression of
Mcm protein and geminin in oral neoplasias, and to the best of our
knowledge, there are no data about the immunohistochemical
expression of these proteins in intramucosal nevi and primary oral
melanomas [2,7,8].
Minichromosome maintenance 2, Ki-67, and geminin were rarely
expressed in intramucosal nevi, with LI less than 1% in all cases. These
data are in accordance with literature reports of low or undetectable
expression of proliferation markers in benign cutaneous melanocytic
lesions, conﬁrming the benign biologic behavior of these lesions [5].
The immunohistochemical expression of Mcm-2, Ki-67, and geminin
in normal oral stratiﬁed epithelium restricted to the basal and
parabasal compartments, which are common sites of proliferative
cells, was useful as an internal positive control [1].It is interesting that there was a high expression of Mcm-2 in
primary oral melanomas. The LI of Mcm-2 expression was consis-
tently higher than Ki-67 and geminin, all presenting a similar staining
pattern, indicating that Mcm-2 may be a sensitive proliferation
marker of oral melanomas. This has also been shown recently in other
tumors as renal cell carcinoma; hepatocellular carcinoma; and
prostate, bladder and breast cancer as well as in oral squamous cell
carcinoma and salivary gland tumors, that is, the proportion of cells
expressing Mcm-2 is consistently higher than those expressing Ki-67
or geminin [2,4,9-13].
It is important to compare our results in oral melanocytic lesions
with their cutaneous counterpart. In agreement with our results, Boyd
et al [5] also demonstrated signiﬁcant differences of Mcm-2
expression between benign nevi and cutaneous melanoma. They
showed high expression of Mcm-2 in primary and metastatic
cutaneous melanoma with mean LI of 49.1% and 40.9%, respectively,
whereas the percentage of positively staining nuclei in benign
cutaneous nevi was only 1.2%. These results may suggest that Mcm-
2 appears to differ signiﬁcantly in melanocytic neoplasms and
potentially provides an additional tool for distinguishing benign
tumors from their malignant counterparts [5].
The differences found in LI of Mcm-2, Ki-67, and geminin in
primary oral melanoma cases may be explained by the different
expression of thesemarkers in the cell cycle phases. It has been shown
that expression of Ki-67 varies in the G1 phase, being present from
late G1 to mitotic phase, whereas Mcm-2 is expressed in the early G1
phase and through the whole cell cycle [14]. Thus, the expression
interval is obviously shorter for Ki-67 than for Mcm-2, which might
result in identiﬁcation of cells in the cell cycle and also noncycling
Fig. 3. Expression of geminin in oral melanocytic lesions: melanocytes of intramucosal nevi showing absence of geminin nuclear expression, whereas the normal oral epithelium is
positive in basal and suprabasal layers (A and B), and invasive oral melanoma presenting nuclear expression of geminin in malignant cells (C and D) (immunoperoxidase, A and C,
original magniﬁcation ×200; B and D, original magniﬁcation ×400).
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showed that Mcm-positive and Ki-67–negative cells have been
characterized as nonproliferative, licensed cells, such as oocytes and
premenopausal breast cells [15,16]. Geminin is a negative regulator of
DNA replication by preventing Cdt1 from loading Mcm proteins onto
DNA, and it is only expressed from S to M phases [2]. Therefore, it is
possible that a proportion of melanocytes cells are in a primed
replication licensed state characterized by Mcm-2 expression and
absence of Ki-67 and geminin, as shown in epithelial tumors studies
[2,17]. Therefore, similar to data described for other tumors, our study
suggests that Mcm-2 is a more sensitive proliferation marker in
primary oral melanomas compared with Ki-67 and geminin.
The present study did not consider the relation between expression
levels of these proliferations markers with prognosis of oral melano-
ma, but it is well known that oral melanoma has a poor prognosis. In
most cancer, high proliferative indices are usually related to a poorer
prognosis [9-13,18]. Nevertheless, some authors demonstrated that
high geminin LI is a signiﬁcant predictor of better prognosis in some
tumors such as oral squamous cell carcinoma, rectal cancer, and high-
grade astrocytic brain tumors. This was explained by the higher
chemoradiosensitivity of geminin-positive cells, during the G2 or M
phase [4,19,20].
In summary, our ﬁndings show that Mcm-2, Ki-67, and geminin
were rarely expressed in intramucosal nevi. In contrast, oral
melanomas showed high levels of these cell proliferations markers,
andMcm-2may be amore sensitive marker compared with Ki-67 and
geminin. These markers may be involved in the pathogenesis of oral
melanomas and could be eventually useful as an additional diagnostic
tool for differential diagnoses of oral benign and malignant melano-cytic lesions. Further evaluation about expression of these prolifera-
tive markers may be useful in delineating the biologic behavior of
these tumors and warrants additional research.Acknowledgments
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